Fusion Pharmaceuticals Inc (FUSN) Shares Plummet Below 1-Year High

Fusion Pharmaceuticals Inc (NASDAQ: FUSN)’s stock price has dropped by -0.05 in relation to previous closing price of 21.29. Nevertheless, the company has seen a loss of -0.09% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-25 that M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma’s balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.

Is It Worth Investing in Fusion Pharmaceuticals Inc (NASDAQ: FUSN) Right Now?

The 36-month beta value for FUSN is at -0.71. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for FUSN is 52.01M, and currently, shorts hold a 15.23% of that float. The average trading volume for FUSN on April 03, 2024 was 2.20M shares.

FUSN’s Market Performance

The stock of Fusion Pharmaceuticals Inc (FUSN) has seen a -0.09% decrease in the past week, with a 97.22% rise in the past month, and a 157.00% gain in the past quarter. The volatility ratio for the week is 0.48%, and the volatility levels for the past 30 days are at 4.91% for FUSN. The simple moving average for the past 20 days is 36.77% for FUSN’s stock, with a 220.14% simple moving average for the past 200 days.

Analysts’ Opinion of FUSN

Many brokerage firms have already submitted their reports for FUSN stocks, with Raymond James repeating the rating for FUSN by listing it as a “Strong Buy.” The predicted price for FUSN in the upcoming period, according to Raymond James is $15 based on the research report published on December 27, 2023 of the previous year 2023.

Oppenheimer, on the other hand, stated in their research note that they expect to see FUSN reach a price target of $13. The rating they have provided for FUSN stocks is “Outperform” according to the report published on September 29th, 2023.

Raymond James gave a rating of “Outperform” to FUSN, setting the target price at $13 in the report published on June 23rd of the previous year.

FUSN Trading at 62.17% from the 50-Day Moving Average

After a stumble in the market that brought FUSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.75% of loss for the given period.

Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 0.48%, as shares surge +102.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +118.76% upper at present.

During the last 5 trading sessions, FUSN fell by -0.07%, which changed the moving average for the period of 200-days by +358.73% in comparison to the 20-day moving average, which settled at $16.10. In addition, Fusion Pharmaceuticals Inc saw 121.44% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for FUSN

Current profitability levels for the company are sitting at:

  • -47.98 for the present operating margin
  • -7.81 for the gross margin

The net margin for Fusion Pharmaceuticals Inc stands at -45.89. The total capital return value is set at -0.37. Equity return is now at value -49.34, with -37.59 for asset returns.

Based on Fusion Pharmaceuticals Inc (FUSN), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.07. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -39.44.

Currently, EBITDA for the company is -97.89 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 866.3. The receivables turnover for the company is 0.49for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.01.

Conclusion

In conclusion, Fusion Pharmaceuticals Inc (FUSN) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts